Johnson & Johnson vs Eli Lilly: a complete comparison of OVR ratings, fundamentals, volatility, and characteristics.
JNJ is rated 85 OVR (A-Tier (Strong)) — Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 co
LLY is rated 91 OVR (S-Tier (Elite)) — Eli Lilly's Mounjaro and Zepbound obesity drugs represent a generational product cycle. Demand subst
| METRIC | JNJ (Johnson & Johnson) | LLY (Eli Lilly) |
|---|---|---|
| OVR Rating | 85 | 91 |
| Tier | A-Tier (Strong) | S-Tier (Elite) |
| Momentum | 45/100 | 80/100 |
| Stability | 92/100 | 85/100 |
| Value Score | 75/100 | 50/100 |
| Revenue Growth | +5% | +36% |
| P/E Ratio | 14x | 48x |
| Beta (Volatility) | 0.45 | 0.65 |
| Market Cap | $380B | $740B |
| Dividend Yield | 3.3% | 0.6% |
| S&P 500 | Yes | Yes |
| NFL Comparison | Frank Gore | Patrick Mahomes |
| Sector | Healthcare | Healthcare |
Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 consecutive years — one of the longest streaks of any public company.
Eli Lilly's Mounjaro and Zepbound obesity drugs represent a generational product cycle. Demand substantially exceeds supply. The obesity drug market is projected to be over $100 billion annually by 2030.
Explore both on MarketMVP
Free platform · Sports-style player ratings for every stock
OPEN MARKETMVP FREE →Educational purposes only. MarketMVP OVR scores, tiers, and athlete comparisons are proprietary educational tools — not financial advice, investment ratings, or recommendations to buy or sell any security. Always conduct your own research. Full disclaimer